Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Taiji Asami"'
Publikováno v:
Biochemistry and Biophysics Reports, Vol 12, Iss C, Pp 135-139 (2017)
The blood-brain barrier (BBB) is a major obstacle to drug delivery into the central nervous system (CNS), in particular for macromolecules such as peptides and proteins. However, certain macromolecules can reach the CNS via a receptor-mediated transc
Externí odkaz:
https://doaj.org/article/c3701501e0e04ec8a958827566dd81b9
Autor:
Kotaro Sakamoto, Yoko Kanematsu-Yamaki, Yusuke Kamada, Masahiro Oka, Toshiyuki Ohnishi, Masanori Miwa, Taiji Asami, Hiroshi Inooka
Publikováno v:
Biochemistry and Biophysics Reports, Vol 11, Iss C, Pp 33-39 (2017)
ActRIIB (activin receptor type-2B) is an activin receptor subtype constitutively expressed in the whole body, playing a role in cellular proliferation, differentiation, and metabolism. For its various physiological activities, ActRIIB interacts with
Externí odkaz:
https://doaj.org/article/45d8df8431974c9889a7941bd6119f0a
Autor:
Naoki Nishizawa, Ayumu Niida, Yasushi Masuda, Satoshi Kumano, Kotaro Yokoyama, Hideki Hirabayashi, Nobuyuki Amano, Tetsuya Ohtaki, Taiji Asami
Publikováno v:
ACS Omega, Vol 2, Iss 5, Pp 2200-2207 (2017)
Externí odkaz:
https://doaj.org/article/9080cf6cfdec4c20a40f9c5239981ffe
Autor:
Tomonobu M. Watanabe, Takayuki Kawai, Masahiko Ohkubo, Taiji Asami, Makiko Morita, Yasuhiro Mihara
Publikováno v:
Analytical Chemistry. 93:3370-3377
Cyclic peptides (CPs) have attracted attention as next-generation drugs because they possess both cell-permeable potential as small molecules and specific affinity similar to antibodies. As intracellular molecules are important targets of CPs, quanti
Autor:
Junichi Sakamoto, Kazue Tsuchimori, Yoshimasa Ishimura, Taiji Asami, Taisuke Mochida, Hideki Hirabayashi, Yoko Kanematsu-Yamaki, Tomoko Asakawa, Mariko Yoneyama-Hirozane, Yusuke Adachi, Naoki Nishizawa, Kouta Matsumiya, Hisashi Fujita, Hideo Fukui, Shiro Takekawa, Ayumu Niida
Publikováno v:
Bioorganic & Medicinal Chemistry. 26:566-572
Neuropeptide Y2 receptor (Y2R) agonism is an important anorectic signal and a target of antiobesity drug discovery. Recently, we synthesized a short-length Y2R agonist, PYY-1119 (4-imidazolecarbonyl-[ d -Hyp24,Iva25,Pya(4)26,Cha27,36,γMeLeu28,Lys30,
Autor:
Tomoko Asakawa, Kotaro Yokoyama, Junichi Sakamoto, Kouta Matsumiya, Hiroaki Nagai, Yoko Kanematsu-Yamaki, Shiro Takekawa, Taiji Asami, Jiro Noguchi, Hisashi Fujita, Hiroshi Inooka, Tomoko Kaisho, Kazue Tsuchimori, Katsuko Dote, Naoki Nishizawa, Tetsuya Ohtaki
Publikováno v:
British Journal of Pharmacology. 175:359-373
Background and Purpose Neuromedin U (NmU) may be a novel target for obesity treatment owing to its anorectic and energy expenditure enhancing effects. Although two receptors, NMU1 and NMU2, are both responsible for the NmU-mediated anti-obesity effec
Publikováno v:
Biochemistry and Biophysics Reports
Biochemistry and Biophysics Reports, Vol 12, Iss C, Pp 135-139 (2017)
Biochemistry and Biophysics Reports, Vol 12, Iss C, Pp 135-139 (2017)
The blood-brain barrier (BBB) is a major obstacle to drug delivery into the central nervous system (CNS), in particular for macromolecules such as peptides and proteins. However, certain macromolecules can reach the CNS via a receptor-mediated transc
Autor:
Taiji Asami, Naoki Nishizawa, Hiroaki Nagai, Yoko Kanematsu-Yamaki, Ayako Shimizu, Shiro Takekawa, Hisashi Fujita, Masaaki Funata, Junichi Sakamoto
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:4626-4629
Neuromedin U (NMU) mediates various physiological functions via NMUR1 and NMUR2 receptors. NMUR2 has been considered a promising treatment option for diabetes and obesity. Although NMU-8, a shorter peptide, has potent agonist activity for both recept
Autor:
Kotaro Yokoyama, Naoki Nishizawa, Ayumu Niida, Yoko Kanematsu-Yamaki, Tetsuya Ohtaki, Yasushi Masuda, Yoko Noguchi, Satoshi Kumano, Yusuke Adachi, Taiji Asami, Shiro Takekawa, Nobuyuki Amano, Tomoko Asakawa, Hideki Hirabayashi
Publikováno v:
Bioorganic & Medicinal Chemistry. 25:5718-5725
Continuous administration of a 14-amino acid peptide YY (PYY) analog, Ac-[d-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys30]PYY(23-36) (4), which has a high binding affinity and agonist activity for the neuropeptide Y2 receptor (Y2R), has previously shown an
Autor:
Taiji Asami, Masahiro Oka, Yusuke Kamada, Yoko Kanematsu-Yamaki, Toshiyuki Ohnishi, Masanori Miwa, Kotaro Sakamoto, Hiroshi Inooka
Publikováno v:
Biochemistry and Biophysics Reports
Biochemistry and Biophysics Reports, Vol 11, Iss C, Pp 33-39 (2017)
Biochemistry and Biophysics Reports, Vol 11, Iss C, Pp 33-39 (2017)
ActRIIB (activin receptor type-2B) is an activin receptor subtype constitutively expressed in the whole body, playing a role in cellular proliferation, differentiation, and metabolism. For its various physiological activities, ActRIIB interacts with